JP6987840B2 - Ｉｄｏ１酵素イメージングのための放射性リガンド - Google Patents

Ｉｄｏ１酵素イメージングのための放射性リガンド Download PDF

Info

Publication number
JP6987840B2
JP6987840B2 JP2019503232A JP2019503232A JP6987840B2 JP 6987840 B2 JP6987840 B2 JP 6987840B2 JP 2019503232 A JP2019503232 A JP 2019503232A JP 2019503232 A JP2019503232 A JP 2019503232A JP 6987840 B2 JP6987840 B2 JP 6987840B2
Authority
JP
Japan
Prior art keywords
ido1
tissue
radiolabeled compound
composition
pet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527225A (ja
JP2019527225A5 (enExample
Inventor
デイビッド・ジェイ・ドネリー
エリン・リー・コール
リチャード・チャールズ・バレル
ウェスリー・エイ・ターリー
アルバン・ジェイ・アレントフ
マイケル・アーサー・ウォレス
ジェイムズ・アーロン・バログ
オードリス・ホアン
メッテ・スキンビェア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019527225A publication Critical patent/JP2019527225A/ja
Publication of JP2019527225A5 publication Critical patent/JP2019527225A5/ja
Application granted granted Critical
Publication of JP6987840B2 publication Critical patent/JP6987840B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Quinoline Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019503232A 2016-07-19 2017-07-18 Ｉｄｏ１酵素イメージングのための放射性リガンド Active JP6987840B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662364020P 2016-07-19 2016-07-19
US62/364,020 2016-07-19
PCT/US2017/042510 WO2018017529A1 (en) 2016-07-19 2017-07-18 Radioligands for imaging the ido1 enzyme

Publications (3)

Publication Number Publication Date
JP2019527225A JP2019527225A (ja) 2019-09-26
JP2019527225A5 JP2019527225A5 (enExample) 2020-08-20
JP6987840B2 true JP6987840B2 (ja) 2022-01-05

Family

ID=59416832

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503232A Active JP6987840B2 (ja) 2016-07-19 2017-07-18 Ｉｄｏ１酵素イメージングのための放射性リガンド

Country Status (13)

Country Link
US (2) US20190282714A1 (enExample)
EP (1) EP3487516A1 (enExample)
JP (1) JP6987840B2 (enExample)
KR (1) KR102513886B1 (enExample)
CN (1) CN109475594A (enExample)
AU (1) AU2017298262B2 (enExample)
BR (1) BR112019000499A2 (enExample)
CA (1) CA3031079A1 (enExample)
EA (1) EA039877B1 (enExample)
IL (1) IL264187B (enExample)
MX (1) MX2019000508A (enExample)
SG (1) SG11201900336YA (enExample)
WO (1) WO2018017529A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526504A (ja) * 2017-06-30 2020-08-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019528300A (ja) * 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼの阻害剤およびその使用方法
KR20200088410A (ko) * 2017-11-21 2020-07-22 광동 오포 모바일 텔레커뮤니케이션즈 코포레이션 리미티드 정보 전송 방법, 네트워크 디바이스 및 단말기 디바이스
EP3720843A1 (en) * 2017-12-05 2020-10-14 GlaxoSmithKline Intellectual Property Development Limited Modulators of indoleamine 2,3-dioxygenase
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101182359A (zh) * 2007-11-09 2008-05-21 中山大学 人吲哚胺2,3-双加氧酶多克隆抗体及其制备方法和应用
WO2011109262A2 (en) * 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
WO2016040458A2 (en) * 2014-09-09 2016-03-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pet probes of radiofluorinated carboximidamides for ido-targeted imaging
UY36390A (es) * 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020526504A (ja) * 2017-06-30 2020-08-31 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法
JP7315483B2 (ja) 2017-06-30 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法
US11919863B2 (en) 2017-06-30 2024-03-05 Bristol-Myers Squibb Company Substituted quinolinylcyclohexylpropanamide compounds and improved methods for their preparation

Also Published As

Publication number Publication date
BR112019000499A2 (pt) 2019-04-24
US20190282714A1 (en) 2019-09-19
US20220305144A1 (en) 2022-09-29
JP2019527225A (ja) 2019-09-26
AU2017298262B2 (en) 2024-07-18
IL264187A (en) 2019-02-28
CA3031079A1 (en) 2018-01-25
KR102513886B1 (ko) 2023-03-27
WO2018017529A1 (en) 2018-01-25
KR20190030727A (ko) 2019-03-22
AU2017298262A1 (en) 2019-03-07
EP3487516A1 (en) 2019-05-29
CN109475594A (zh) 2019-03-15
EA201990198A1 (ru) 2019-06-28
SG11201900336YA (en) 2019-02-27
IL264187B (en) 2021-06-30
MX2019000508A (es) 2019-03-28
EA039877B1 (ru) 2022-03-23

Similar Documents

Publication Publication Date Title
JP6987840B2 (ja) Ｉｄｏ１酵素イメージングのための放射性リガンド
TWI589302B (zh) 用於合成造影劑及其中間體之方法及裝置
TWI592391B (zh) 用於合成及使用造影劑之組合物、方法及系統
EP3866692B1 (en) Radioligands for imaging the lpa1 receptor
HUE034027T2 (en) Psma-binding agents and uses thereof
JP6927974B2 (ja) 放射性標識ｍＧｌｕＲ２／３ＰＥＴリガンド
EP3062827A1 (en) Radioligands for imaging the lpa-1 receptor
WO2014052454A1 (en) Imaging agents
US9956303B2 (en) Anti-met therapy for previously diagnosed cancer patients
KR20120120957A (ko) 골 전이 영상화용 ｆ18?티로신 유도체
JP6913101B2 (ja) 放射性標識大環状ｅｇｆｒ阻害剤
CN102223900A (zh) 用于多巴胺d2受体的成像配体
AU2016308145A1 (en) Radioactive halogen-labeled pyrido(1,2-a)benzimidazole derivative compound
US20250222145A1 (en) Tracer composition for radioactive pet diagnosis, intermediate thereof, and production method thereof
KR101519006B1 (ko) 신규한 벤즈아마이드 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 피부암 진단용 약학적 조성물
JP2015500873A (ja) 心筋灌流イマジニング用造影剤
US20250340562A1 (en) Chromane imaging ligands
TW202543598A (zh) 一種靶向成纖維細胞活化蛋白結合化合物、同位素標記物及其用途
HK40029571B (zh) 伊文思蓝衍生物的化学缀合物及其作为靶向前列腺癌的放射疗法和显像剂的用途
JPWO2020045638A1 (ja) 放射性イミダゾチアジアゾール誘導体化合物
L’Estrade et al. Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial. Menu

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211201

R150 Certificate of patent or registration of utility model

Ref document number: 6987840

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250